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Approximately 30–40% of male and 8–16% of female carriers of the Fragile X
premutation will develop a neurodegenerative movement disorder characterized
by intentional tremor, gait ataxia, autonomic dysfunction, cognitive decline, and
Parkinsonism during their lifetime. At the molecular level, premutation carriers have
increased expression levels of the FMR1 and the antisense FMR1 (ASFMR1) mRNAs.
Both genes undergo alternative splicing giving rise to a number of different transcripts.
Alteration in the alternative splicing process might be associated with FXTAS. In this
study, we have investigated the correlation between objective measures of movement
(balance and tremor using the CATSYS battery) and the expression of both the FMR1
and the ASFMR1 genes. In addition, we investigated whether their expression level
and that of the ASFMR1 131 bp splice isoform could distinguish between premutation
carriers with FXTAS and non-FXTAS premutation carriers. Confirming previous findings,
the expression levels of transcripts at the FMR1 locus positively correlated with the
CGG repeat number and significantly differentiated the premutation carriers from the
control groups. Furthermore, premutation carriers with and without FXTAS, showed a
significant difference in the expression level of the ASFMR1 131 bp splice isoform when
compared to age and gender matched controls. However, there was no significant
difference in the ASFMR1 131 bp splice isoform expression level when comparing
premutation carriers with and without FXTAS. Finally, our results indicate significant
group differences in CATSYS dominant hand reaction time and postural sway with
eyes closed in premutation carriers without FXTAS compared to controls. In addition,
a significant inverse association between the tremor intensity and the expression level
of ASFMR1 131 bp splice isoform in premutation carriers compared to controls, was
observed, suggesting a potential role in the pathogenesis of FXTAS.
Keywords: FMR1, ASFMR1, transcription, premutation, FXTAS, CATSYS, splicing isoforms
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INTRODUCTION
Individual carriers of a premutation allele in the FMR1
gene (55–200 CGG repeats) are at risk of developing Fragile
X-associated tremor/ataxia syndrome (FXTAS) a late onset
neurodegenerative disorder characterized by intentional tremor,
gait ataxia, autonomic dysfunction, and Parkinsonism (Tassone
and Hall, 2016). Cognitive decline, particularly frontal executive
dysfunction, is also very common (Allen et al., 2008; Grigsby
et al., 2008). Approximately 46% of males and 17% of
females will develop and be affected by FXTAS during their
lifetime. The onset of the motor signs in men is typically
in the early 60s (Tassone et al., 2007) and the penetrance
is age-related, such that 75% of men ≥80 years of age are
affected (Jacquemont et al., 2004). Patients with FXTAS have
several types of motor dysfunction, hence they are considered
within the combinational movement disorders (Hall et al.,
2014).
A higher frequency of a number of phenotypes including
psychiatric conditions, dysautonomia, sleep apnea, hypertension,
migraine, rheumatologic conditions, endocrine diseases, seizures,
peripheral neuropathy, immune mediated conditions (such as
fibromyalgia and hypothyroidism) has also been described in
premutation carriers (reviewed in Hagerman and Hagerman,
2016).
Several molecular mechanisms have been proposed to
contribute to the different phenotypes observed in the
FMR1- associated disorders. One of the main mechanisms
proposed to lead to the premutation pathogenesis is RNA
toxicity due to the 2 to 8-fold increase in the FMR1 mRNA
expression levels observed in premutation carriers (Tassone
et al., 2000; Kenneson et al., 2001; Allen et al., 2005). RNA
TABLE 1 | Patient demographics by group.
Control (n = 26) Premutation (n = 52) p-value Adjusted p-value
Age (years) 0.1488 0.4408
N 26 46
Mean (SD) 55.6 (8.7) 59.3 (8.3)
Median (range) 55.5 (40− 68) 61 (40− 78)
Primary race (n, %) 0.4408 0.4408
Asian 1 (3.8%) 1 (1.9%)
Black or African American 1 (3.8%) 0
White 22 (84.6%) 42 (80.8%)
Not reported 2 (7.7%) 9 (17.3%)
Primary ethnicity 0.3588 0.4408
Hispanic or Latino 3 (11.5%) 2 (3.8%)
Not hispanic or latino 18 (69.2%) 32 (61.5%)
Not reported 5 (19.2%) 18 (34.6%)
Handedness 0.2442 0.4408
Right 22 (84.6%) 43 (82.7%)
Left 4 (15.4%) 3 (5.8%)
Not reported 0 6 (11.5%)
Education level 0.3798 0.4408
High school/GED 2 (7.7%) 2 (3.8%)
Partial college 3 (11.5%) 11 (21.2%)
BA/BS 11 (42.3%) 12 (23.1%)
MA/MS/PhD/MD 10 (38.5%) 20 (38.5%)
Not reported 0 7 (13.5%)
Yearly household income 0.2827 0.4408
25–50 K 2 (7.7%) 2 (3.8%)
50–75 K 2 (7.7%) 7 (13.5%)
75–100 K 5 (19.2%) 4 (7.7%)
100–150 K 8 (30.8%) 12 (23.1%)
150–250 K 5 (19.2%) 6 (11.5%)
>250 K 1 (3.8%) 9 (17.3%)
Not reported 3 (11.5%) 12 (23.1%)
Marital status 0.0728 0.4408
Married/partner 19 (73.1%) 42 (80.8%)
Divorced 2 (7.7%) 2 (3.8%)
Single 4 (15.4%) 1 (1.9%)
Not reported 1 (3.8%) 7 (13.5%)
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toxicity leads to protein sequestration where the expanded
CGG repeat sequesters a number of CGG binding proteins,
hence, partially or fully impairing their normal function in the
cell (Hagerman and Hagerman, 2015). Recently, a non-AUG
initiated (RAN) translation, where a polyglycine-containing
protein, FMRpolyG is generated by initiating at non-AUG
codons located upstream of the CGG-repeat region (Todd et al.,
2013), has been proposed as a key mechanism contributing to
neurodegeneration. Further, DNA damage has been proposed as
a pathological model due to the formation of co-transcriptional
R-loops which trigger a DNA damage response (DDR) leadings
to neuronal death (Ginno et al., 2013; Hamperl and Cimprich,
2014; Loomis et al., 2014; Julie and Karlene, 2015).
In an effort to elucidate other mechanistic pathways that might
be involved in FXTAS, Ladd et al. (2007) identified a novel gene,
the antisense FMR1 (ASFMR1), the main identified non-coding
RNA (ncRNA) at the FMR1 locus. The gene includes the CGG
repeat region of the FMR1 gene in the antisense orientation.
Its expression is driven by two promoters that are flanked by
CTCF-binding sites, the FMR1 bidirectional promoter and a
second one located in the second intron of the FMR1 gene (Ladd
et al., 2007). Similarly, to the FMR1 gene, the levels of expression
of ASFMR1 mRNA are elevated in the cells derived from
premutation carriers compared to controls (Ladd et al., 2007;
Loesch et al., 2011) while no expression is detected in patients
with Fragile X syndrome. Furthermore, the ASFMR1 transcript
undergoes to premutation-specific alternative splicing which
might be potentially associated with FXTAS and other FMR1
associated disorders (Ladd et al., 2007; Hall et al., 2017).
Loesch et al. (2011) showed that the elevated sense/antisense
FMR1 transcript levels in the gray zone (40–54 CGG repeats)
and in premutation carriers might contribute to the development
of a parkinsonian phenotype due to mitochondrial dysfunction
that leads to progressive neurodegeneration. A recent study by
Hall et al. (2017) showed that both male and female premutation
carriers had higher expression levels of ASFMR1 splice isoform
corresponding to the isoform described by Ladd et al. (2007),
compared to controls after adjusting for age, confirming previous
finding Ladd et al. (2007). Although the authors suggested
ASFMR1 splice isoform as a predictor of FXTAS, they reported
that there was no significant difference in the expression levels
between non-FXTAS premutation carriers and FXTAS patients
(Hall et al., 2017).
Besides the molecular measures, clinical measures have a
significant role in monitoring premutation carriers with and
without FXTAS. A computerized coordination-tremor-balance
test system (CATSYS) is one of the important clinical assessments
for FXTAS. It is a quantitative neurological test battery used to
quantify movement abnormalities (tremor and ataxia) recording
five main neuromotor control measures. Previous studies
reported on the sensitivity of the test in identifying preclinical
symptoms of FXTAS (Allen et al., 2008) and on its ability
to differentiate between premutation carriers with FXTAS and
controls (Aguilar et al., 2008; Narcisa et al., 2011).
In this study, we investigated the correlation between levels of
mRNA expression of the FMR1 locus (mRNA expression levels
of the FMR1 and of the ASFMR1 genes and of the ASFMR1
TABLE 2 | Trio study subjects.
Trio # Category CGG # Age FXTAS stage
1 FXTAS 88 64 5
Asymp Pre 75 66 1
Control 31 65 0
2 FXTAS 104 56 4
Asymp Pre 98 59 1
Control 21 50 0
3 FXTAS 119 67 5
Asymp Pre 105 64 0
Control 28 66 0
4 FXTAS 102 69 4
Asymp Pre 110 57 1
Control 29 65 0
5 FXTAS 133 54 4
Asymp Pre 141 52 1
Control 28 53 0
6 FXTAS 96 61 4
Asymp Pre 95 60 1
Control 33 61 0
7 FXTAS 80 79 4
Asymp Pre 80 71 0
Control 32 76 0
8 FXTAS 82 57 4
Asymp Pre 84 51 0
Control 32 52 0
9 FXTAS 103 58 4
Asymp Pre 128 53 0
Control 29 55 0
10 FXTAS 100 56 4
Asymp Pre 80 56 0
Control 28 55 0
11 FXTAS 88 66 4
Asymp Pre 85 63 1
Control 27 64 0
12 FXTAS 83 70 4
Asymp Pre 77 69 1
Control 42 70 0
13 FXTAS 121 76 4
Asymp Pre 67 74 1
Control 28 73 0
14 FXTAS 83 75 4
Asymp Pre 59 76 0
Control 30 79 0
15 FXTAS 95 66 4
Asymp Pre 70 64 1
Control 27 64 0
131 bp splice isoform) and a selected group of measures in
the CATSYS associated with the core symptoms of FXTAS
(tremor and balance) in the non-FXTAS premutation carriers
compared to controls. In addition, we investigated whether
there was a differential transcript profile at the FMR1 locus
expression between premutation carriers with and without
FXTAS compared to controls. The main aim of the study was to
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determine whether a combination of neurological and molecular
measures could help predict the prognosis of non-FXTAS male
premutation carriers.
MATERIALS AND METHODS
Participants
Individuals were recruited through the MIND Institute
Fragile X Research and Treatment Center, by postings in the
community, from flyers posted through the National Fragile X
Foundation, from over 1,200 extended pedigrees of probands
with Fragile X-associated disorders seen for clinical care or for
being participants in research studies involving non-FXTAS
premutation carriers, carried out at the MIND Institute.
Participants provided informed consent according to protocols
approved by the UC Davis Institutional Review Board. Biological
samples were collected under protocols approved by the UC
Davis Institutional Review Board.
Participants included 52 non-FXTAS male premutation
carriers (mean age = 59.3, SD = 8.3) and 26 healthy controls
(mean age = 55.6, SD = 8.7) (Table 1).
In addition, we investigated the difference in expression levels
of transcripts at the FMR1 locus in 15 trios. Each trio was
age-matched, and included a male premutation carrier with
FXTAS (FXTAS stage 4 or 5) (n = 15), a non-FXTAS male
premutation carrier (FXTAS stage 0 or 1) (n = 15) and a healthy
control (n = 15) (total of 45 participants).
Group status for each participant was confirmed through
DNA testing as having 55–200 CGG repeats (carriers of the
FMR1 premutation), or having 5–44 CGG repeats (normal range,
comparison group). Individuals who had a gray zone allele
(45–54 CGG repeats) or a full mutation (<200 CGG repeats)
were not included in this study.
Clinical Measures
CATSYS included various tasks grouped into five existing
categories (Després et al., 2000): postural tremor, intentional
tremor, postural sway, manual coordination, and reaction time.
All tasks were appended to the standard CATSYS protocol and
analyzed accordingly.
The CATSYS measures were administered as described in
Aguilar et al. (2008). Postural tremor was measured per the
CATSYS protocol. For both dominant and non-dominant hands,
the patient was asked to grasp a Tremor Pen R© (it contains a
biaxial micro-accelerometer to measure the movement in plane
perpendicular to the axis of the pen) and hold it as steadily as
possible four inches in front of the navel. For the intention tremor
performance task, the patient was asked to grip the pen in the
same way as in the postural tremor task, yet not in a steady
position, but to alternately tap the centers of two points located
on either side of the computer screen, designated as points A and
B, for each hand.
As for the postural sway protocol, patients were asked to
stand on the force plate for 30 and 10 s, once with the
eyes open and once closed. Manual hand coordination was
measured by asking patients to rhythmically tap the drum
in time with sounds generated by the CATSYS program.
The testing using this category was completed with assessing
the finger coordination, which included the rhythmic tapping
of the right and left index finger. Finally, the reaction
time for response, which was an auditory stimulus, in
this case was recorded using the reaction handle of the
CATSYS system. The duration for testing each hand was
40 s where the auditory stimuli were triggered at random
intervals.
Molecular Measures
DNA and RNA Isolation
Genomic DNA was isolated from peripheral blood lymphocytes
(5 ml of whole blood using standard methods; Qiagen, Valencia,
CA, United States). The CGG size of the premutation and
normal alleles were obtained using a combination of Southern
Blot and PCR analysis. For Southern blot analysis, 5–10 µg
of isolated genomic DNA was digested with EcoRI and
NruI. Probe hybridization used the FMR1-specific dig-labeled
StB12.3. Details are as previously described (Tassone et al.,
2008). PCR analysis was performed using the AmplideX
PCR/CE FMR1 Reagents (Asuragen, Inc.) as described in
Filipovic-Sadic et al. (2010). Total RNA was isolated from
2.5 ml of peripheral blood collected in PAXgene Blood
RNA tubes using the PAXgene Blood RNA Kit (Qiagen,
Valencia, CA, United States) and quantified using NanoDrop.
cDNA synthesis reaction was as described by Tassone et al.
(2000).
Measures of mRNA Expression Levels by qRT-PCR
qRT-PCR was performed using both Assays-on-Demand from
Applied Biosystem (Applied Biosystems, Foster City, CA,
United States) and custom designed TaqMan primers and probe
assays to measure transcripts expression levels. Custom designed
primers and probe were used for normalization (Tassone et al.,
2000). Custom designed primers and probe were also designed to
quantify the ASFMR1 gene and the ASFMR1 splice isoform (Ladd
et al., 2007).
Statistical Analysis
Left- and right-handed clinical measures were converted to
dominant and non-dominant based on the patient’s handedness;
if handedness information was missing measures from the right
hand were used for the dominant side. A patient with a CGG
repeat ranging from 110 to 130 was assigned a repeat length of
120 for analysis purposes.
By visual inspection, CATSYS data deviated substantially
from a normal distribution both on the original scale and
on the log scale (other transformations were not considered,
as model coefficients estimated based on these are rather less
interpretable than the aforementioned scales). Therefore, non-
parametric methods were used throughout for analysis of these
data.
Age, clinical measures, and molecular measures were
compared between groups using Wilcoxon rank sum tests.
Distributions of categorical demographic characteristics
were compared between groups using Fisher’s exact test.
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TABLE 3 | CATSYS clinical measures in both normal and premutation carrier groups.
Control Premutation p-value Adjusted
p-value
Mean (SD) Median (range) Mean (SD) Median (range)
Reaction time test for dominant
hand: average reaction time
0.204 (0.02) 0.2 (0.159− 0.239) 0.23 (0.032) 0.23 (0.167− 0.295) 0.0011 0.0094
Sway closed 30: sway area 454 (402) 403 (5− 1703) 802 (580) 653 (11− 2,300) 0.0033 0.0176
Sway closed 10: sway area 218 (189) 198 (0− 799) 500 (445) 325 (8− 1,988) 0.0012 0.0094
Reaction time test for
non-dominant hand: average
reaction time
0.198 (0.025) 0.198 (0.137− 0.236) 0.218 (0.035) 0.212 (0.163− 0.318) 0.0463 0.1234
Dominant foot: sway area 568 (300) 570 (18− 1,169) 1107 (1,001) 698 (9− 4,203) 0.0394 0.1234
Non-dominant foot: sway area 538 (452) 419 (13− 1,713) 842 (672) 685 (6− 3035) 0.0287 0.1147
Significant values are indicated in bold.
FIGURE 1 | Plots showing the correlation between the expression level of the ASFMR1 spicing isoform 131 bp mRNA and tremor intensity in the non-dominant
hand (A), tremor intensity in the dominant hand (B), and tremor intensity while writing with dominant hand (C) in controls compared to premutations without FXTAS.
Correlations were estimated and tested using the Spearman
(non-parametric) correlation. Clinical measures were
compared between visits using the Wilcoxon signed-rank
test.
In the trios study, expression levels of ASFMR1, the splice
isoform, and FMR1 were compared among premutation
participants with FXTAS, premutation participants with
non-FXTAS, and control subjects using linear models. Age and
CGG repeat number were adjusted for by including these as
covariates in each model. Post hoc pairwise comparisons between
groups were conducted using the Tukey HSD method. Analyses
were conducted using R, version 3.4.2 (R Core Team, 2017).
p-values were adjusted for multiple testing within each table
using the Benjamini–Hochberg method.
RESULTS
Demographics
In this study, among the total 78 subjects, 82.1% (n = 64) were
Caucasian and 38.5% (n = 30) had a higher degree education
(MA/MS/PhD/MD). In addition, 83.3% (n = 65) were right
hand dominant. The demographics data showed no statistical
significant difference between any of the groups (Table 1).
As for the trio study, participants were individually matched
for CGG repeats and age; where the mean age (SD) for the 15
controls was 63 (±8.9), for the 15 FXTAS premutation carriers
was 65 (±8), and for the 15 non-FXTAS premutation carriers
was 62 (±8). The mean (SD) for the CGG repeat number was
98.47 (±15.8) in male premutation carriers with FXTAS, 90.27
(±22.8) in non-FXTAS premutation carriers and 29.67 (±4.4)
in controls (Table 2). The mean (SD) of the FMR1 mRNA was
2.9 (±0.6) in the premutation with FXTAS, 1.9 (±1.1) in the
non-FXTAS premutation and 1.4 (±0.4) in controls. The mean
of the ASFMR1 mRNA was 0.51 (±0.3) in the premutation
with FXTAS, 0.53 (±0.3) in the non-FXTAS premutation and
0.3 (±0.1) in controls. The mean of the ASFMR1 131 bp splice
isoform mRNA was 1.9 (±1.6) in the premutation with FXTAS,
1.7 (±2.1) in the non-FXTAS premutation and 0.1 (±0.1) in
controls.
A Subset of CATSYS Clinical Measures
Differentiate Between Non-FXTAS
Premutation Carriers and Controls
Three CATSYS performance measures were found to be
significantly different between non-FXTAS premutation carriers
and controls; the reaction time test for dominant hand (Average
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FIGURE 2 | Box plots showing the expression of FMR1 (A), ASFMR1 (B), and ASFMR1 131 bp splicing isoform (C) in premutation carriers compared to controls.
Correlation between CGG repeat number and the expression levels of (D) FMR1, (E) ASFMR1, and (F) ASFMR1 131 bp splicing isoform mRNAs.
TABLE 4 | Summary of expression by group.
Normal Premutation p-Value Adjusted p-value
Mean (SD) Median (range) Mean (SD) Median (range)
FMR1 1.24 (0.21) 1.25 (0.83–1.64) 2.44 (0.74) 2.29 (0.63–4.41) <0.0001 <0.0001
ASFMR1 1.38 (1.09) 1.33 (0–3.64) 2.83 (5.35) 1.47 (0.14–34.29) 0.0889 >0.9999
ASFMR1 131 bp splicing isoform 0.24 (0.52) 0.02 (0–1.95) 8.14 (16.75) 2.04 (0–103.53) <0.0001 <0.0001
Significant values are indicated in bold.
TABLE 5 | Correlations between molecular measures and CGG repeat numbers.
Normal Premutation
Correlation p-Value Adjusted p-value Correlation p-Value Adjusted p-value
FMR1 0.13 0.542 >0.9999 0.76 <0.0001 <0.0001
ASFMR1 0.03 0.8659 >0.9999 0.09 0.5046 0.5046
ASFMR1 131 bp splicing isoform 0.04 0.8424 >0.9999 0.46 0.0006 0.001
Significant values are indicated in bold.
reaction time) (p = 0.0094), the 30 s postural sway test with eyes
open (p = 0.0176), and the 10 s postural sway test with eyes
closed (p = 0.0094) (Table 3). This means that both the reaction
time and the sway area are significantly increased in non-FXTAS
premutation carriers compared to controls.
On the other hand, a subset of measures lost their significance
upon correction for multiple testing; reaction time test for
non-dominant hand (average reaction time) (p = 0.0463),
dominant foot (sway area) (p = 0.0394) and non-dominant foot
(sway area) (p = 0.0287).
Impact of Age, CGG Repeat Number,
Expression Levels of FMR1, ASFMR1,
and ASFMR1 Splice Isoform mRNAs on
CATSYS Measures
A significant correlation between the non-dominant hand
tremor intensity and the ASFMR1 131 bp splicing isoform
was observed in non-FXTAS premutation carriers (p = 0.0304)
but not in controls (p = 0.3363) (Figure 1A). The expression
level of ASFMR1 131 bp splicing isoform showed a significant
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D E F
FIGURE 3 | Box plots showing differential expression levels of FMR1 (A), ASFMR1 (B) and ASFMR1 131 bp splicing isoform (C) mRNAs in controls compared to
non-FXTAS premutation carriers and FXTAS premutation carriers. FMR1, ASFMR1, and ASFMR1 131 bp splicing isoform mRNAs expression levels, as function of
the CGG repeat number, are shown in D, E and F respectively.
inverse correlation with the non-dominant hand tremor intensity
(−0.44) with the higher splicing isoform expression levels of this
being associated with lower non-dominant hand tremor intensity
score.
Correlation between ASFMR1 131 bp splicing and two
CATSYS performance tasks, tremor intensity of dominant hand
(p = 0.0489) (Figure 1B), and tremor intensity while writing with
dominant hand (p = 0.0268) (Figure 1C) lost significance after
correction for multiple testing.
None of the CATSYS measures showed any statistically
significant association with age, CGG repeat number, expression
levels of FMR1, or ASFMR1 mRNAs.
Expression Levels of Transcripts at the
FMR1 Locus
Premutation carriers (with and without FXTAS) showed
significantly elevated expression of both FMR1 and ASFMR1
131 bp splicing isoform mRNA compared to controls with a
p < 0.0001 in both cases (Figures 2A,C and Table 4). No
significant elevation was observed for the ASFMR1 mRNA
(Figure 2B and Table 4).
None of the molecular measures were significantly correlated
with age. As expected, the CGG repeat number was significantly
correlated with the expression of both FMR1 (p < 0.0001) and
ASFMR1 131 bp splicing isoform mRNAs (p = 0.001) (Table 5
and Figures 2D–F) but not for the ASFMR1 mRNA (Figure 2E
and Table 5).
When analyzing the trios, as expected we observed a
significant higher expression of FMR1 mRNA in the premutation
carriers with FXTAS and without FXTAS compared to control
subjects (Figure 3A; p < 0.001 and p < 0.001, respectively,
Sellier et al., 2014). In addition, we observed significantly higher
expression level of ASFMR1 131 bp splicing isoform mRNA
in both non-FXTAS premutation subjects [p = 0.003, Mean
(SD) = 1.7 (2.1)] and subjects with FXTAS [p = 0.004, Mean
(SD) = 1.9 (1.6)] compared to control subjects [Mean (SD) = 0.1
(0.1)] (Figure 3C). However, the ASFMR1 expression levels
between groups did not reach statistical significance (Figure 3B).
These three molecular measures were significantly correlated
with the number of CGG repeats (Figures 3D–F).
DISCUSSION
This study aimed to identify clinical and molecular
measures that might associate with development of
FXTAS in male Fragile X premutation carriers. CATSYS
is among the helpful tools to distinguish between
premutation carriers with and without FXTAS and controls
because it allows for quantitative documentation of
neuromotor and deficits with minimal operating training
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and time (Aguilar et al., 2008). Specifically, among the measures
found useful, are those that are considered components of the
key FXTAS phenotypic characteristics such as tremor intensity,
postural tremors, and postural sway (Aguilar et al., 2008; Narcisa
et al., 2011). Our previous reports (Aguilar et al., 2008; Narcisa
et al., 2011), looking specifically at the CATSYS measure in FMR1
premutation carriers with and without FXTAS and, unaffected
controls, found the method to be sufficiently accurate for the
cause. In addition, the 2008 study by Allen colleagues showed a
high clinical usefulness of the battery.
In this study, we showed that three CATSYS task performance
measures were significantly different in non-FXTAS male
premutation carriers compared to controls. Two of them were
measures of postural sway, which are associated with ataxia. Our
results appear to be consistent with those of Narcisa et al. (2011),
as both showed that non-FXTAS premutation carriers had higher
postural sway compared to controls. However the significance of
this effect was lost when correcting for multiple testing. Several
factors could explain these findings including the age group of the
non-FXTAS participants (mean = 59.3) compared to the mean of
52.89 in the Narcisa et al. (2011) study. Further, gender might be
another contributing factor, where Narcisa et al. (2011) included
females only, whereas, our study had males only. Hence, a subset
of our subjects might be showing signs of ataxia because of being
older males.
Importantly, this study aimed to identify molecular
biomarkers at the FMR1 locus (FMR1, ASFMR1, and ASFMR1
131 bp splicing isoform) that may correlate with early emergence
of movement abnormalities in premutation carriers without
FXTAS and might be helpful as potential biomarkers in
longitudinal studies. We found an inverse correlation between
both ASFMR1 131 bp splice isoform and tremor intensity for the
non-dominant hand. Thus, using a combination of molecular
and clinical phenotypic measures could help to identify changes
in premutation carriers most at risk for developing FXTAS.
Interestingly, the expression of ASFMR1 131 bp splice isoform
mRNA was higher in premutation carriers overall compared to
controls, but it did not distinguish between non-FXTAS and
FXTAS premutation carrier groups. The function, if any, of this
splicing isoform is currently unknown and the dysregulation
of the alternative splicing process and the levels of expression
of the ASFMR1 could be part of the pathogenesis of FXTAS
as could be the case for the FMR1 gene (Tseng et al., 2017).
Moreover, it was previously found that RAN translation, which
is one of the mechanisms proposed to explain the pathogenesis
of FXTAS, also occurs in the antisense direction generating
novel proteins that accumulate in ubiquitinated inclusions
in FXTAS patients (Krans et al., 2016) further supporting the
potential role of the antisense transcript in FXTAS. Further
studies are needed to shed lights on the significance of
increased expression levels of this isoforms in premutation
carriers.
This study demonstrates that sensitive postural sway and
tremor tests might be used in early identification of premutation
carriers at risk for FXTAS, however, future longitudinal analyses
with larger sample sizes are needed to confirm this hypothesis.
Objective and sensitive movement measures should also be useful
for monitoring disease progression, severity, and response to
intervention. Further studies are warranted to further assess
the correlation between the clinical and molecular measures to
confirm our observations in this study.
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